Involved in SBIR only in the firm's early years and with a single funded project, Natus had over that period been focused to healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care. These include hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. Subsquently the firm shifted focus to providing healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments. In July 2022 ArchiMed - a French private equity fund focused on the healthcare industry - after briefly investing in Natis Medical in July 2022, shortly after that invetsment, completed take-private deal of Natus for $1.1bn
